Loading provider…
Loading provider…
Rheumatology Physician in Altoona, PA
NPI: 1205834397Primary Practice Location
UPMC ALTOONA
2500 7th Ave, Altoona, PA
Primary Employer
Altoona Arthritis & Osteoporosis Center
altoonaarthritis.com
HQ Phone
Get DO Frederick's Phone Numberphone_androidMobile
Get DO Frederick's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardPA State Medical License

PA State License
2000 - 2026

VA State License
1996 - 2000

American Board of Internal Medicine
Rheumatology
National Capital Consortium
Fellowship • 1996 - 1998
1996 - 1998
Residency • 1993 - 1996
1993 - 1996
Pcom
Medical School
Until 1993
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 85025Complete blood cell count (red cells, white blood cell, platelets), automated test | 784 | 1,529 |
| 2 | 85651Red blood cell sedimentation rate, to detect inflammation | 769 | 1,498 |
| 3 | 86140Measurement C-reactive protein for detection of infection or inflammation | 767 | 1,485 |
| 4 | 36415Insertion of needle into vein for collection of blood sample | 750 | 1,463 |
| 5 | 84450Liver enzyme (sgot), level | 729 | 1,444 |
Management of Postmenopausal Osteoporosis
Authors: Panagiota Andreopoulou, Richard Bockman
Publication Date: 2015-01
Authors: Arthur Kavanaugh, M Elaine Husni
Journal: Arthritis Care Res (Hoboken)
Publication Date: 2020-05-15
Golimumab in patients with active rheumatoid arthritis after treatment with tumor necrosis factor α inhibitors: findings with up to five years of treatment in the multicenter, randomized, double-blind, placebo-controlled, phase 3 GO-AFTER study.
Authors: Norman Gaylis, Mittie Doyle
Publication Date: 2015-01
Lead Sponsor: National Cancer Institute (NCI)
Intervention / Treatment: OTHER: Questionnaire Administration, OTHER: Laboratory Biomarker Analysis, BIOLOGICAL: Pembrolizumab, PROCEDURE: Biospecimen Collection, OTHER: Quality-of-Life Assessment, RADIATION: Radiation Therapy, OTHER: Patient Observation
Lead Sponsor: Alliance for Clinical Trials in Oncology
Collaborators: National Cancer Institute (NCI), Medivation, Inc., Astellas Pharma US, Inc., Biologics, Inc.
Intervention / Treatment: DRUG: prednisone, DRUG: enzalutamide, DRUG: abiraterone
Lead Sponsor: National Cancer Institute (NCI)
Intervention / Treatment: OTHER: Laboratory Biomarker Analysis, OTHER: Quality-of-Life Assessment, DRUG: Exemestane, DRUG: Letrozole, DRUG: Anastrozole, DRUG: Tamoxifen Citrate, DRUG: Systemic Chemotherapy